事件:巨子生物获独家专利重组人Ⅳ型胶原蛋白。近日,巨子生物独家专利——重组人Ⅳ型胶原蛋白(中国发明专利:ZL 2024 1 0545206.6)获得国家知识产权局正式授权,这一成果在行业内首次打破传统认知,为Ⅳ型胶原蛋白截短蛋白的应用开辟全新路径。巨子生物重组人Ⅳ型胶原蛋白在修护和舒缓等方面功效突出。巨子生物重组人Ⅳ型胶原蛋白富含整合素位点和抗炎活性三肽,具有提升屏障相关蛋白,抑制炎症因子等多种...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.